Comparative Pharmacology
Head-to-head clinical analysis: HERCESSI versus HERZUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HERCESSI versus HERZUMA.
HERCESSI vs HERZUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It inhibits the proliferation of human tumor cells that overexpress HER2, and mediates antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing cancer cells.
HER2/neu receptor antagonist; binds to extracellular domain of HER2, inhibiting downstream signaling pathways (PI3K/Akt and MAPK), and induces antibody-dependent cell-mediated cytotoxicity (ADCC).
10 mg subcutaneously daily for 21 consecutive days, followed by 7 days off therapy in 28-day cycles.
4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly, or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30-90 minutes every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 2.5–3.5 hours (mean ~3 hours) in patients with normal renal function; prolonged to 6–12 hours in moderate renal impairment and up to 20 hours in severe impairment.
Elimination half-life is approximately 28-38 days (range 21-52 days). The long half-life supports dosing every 3 weeks.
Primarily excreted unchanged in urine via glomerular filtration and active tubular secretion; ~90% of dose recovered in urine as parent drug, ~5% in feces.
Primarily hepatic metabolism; limited renal excretion (<1% unchanged). Biliary/fecal excretion is not a major route.
Category C
Category C
HER2 Inhibitor
HER2 Inhibitor